EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes

Elisabeth Huber iD, Tarini Singh iD, Melanie Bunk iD, Mayscha Hebel iD, Kerstin Kick iD, Andreas Weiß iD, Mirjam Kohls iD, Melanie Köger iD, Maja Hergl iD, Jose Maria Zapardiel Gonzalo iD, Ezio Bonifacio iD, Anette-G Ziegler iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Elisabeth Huber und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich 80939, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Center for Diabetes Research, LifeScience-Stiftung, Juvenile Diabetes Research Foundation International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Staging and monitoring of presymptomatic type 1 diabetes includes the assessment for dysglycemia.

Objective

To assess the ability of continuous glucose monitoring (CGM) to differentiate between islet autoantibody-negative controls and early-stage type 1 diabetes and explore whether CGM classifiers predict progression to clinical diabetes. Research Design and Methods Children and adolescents participating in public health screening for islet autoantibodies in Bavaria, Germany, were invited to undergo CGM with Dexcom G6. In total, 118 participated and valid data was obtained from 97 [57 female; median age 10 (range 3-17) years], including 46 with stage 1, 18 with stage 2, and 33 with no islet autoantibodies.

Results

Mean glucose during CGM in islet autoantibody-negative controls was high (median, 115.3 mg/dL) and varied substantially (interquartile range, 106.8-124.4). Eleven (33%) of the controls had more than 10% of glucose values above 140 mg/dL (TA140). Using thresholds corresponding to 100% specificity in controls, differences between controls and stage 1 and stage 2 were obtained for glucose SD, TA140, TA160, and TA180. Elevations in any 2 of these parameters identified 12 (67%) with stage 2 and 9 (82%) of 11 participants who developed clinical diabetes within 1 year. However, there was marked variation within groups for all parameters and poor consistency observed in a second CGM performed in 18 participants.

Conclusion

This study demonstrated the potential of integrating CGM into staging and monitoring of early-stage type 1 diabetes. However, substantial improvement in the precision of CGM is required for its application in routine monitoring practices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringHumansChildFemaleAdolescentMaleChild, PreschoolDisease ProgressionAutoantibodiesGermanyContinuous Glucose Monitoring

Stichwörter der Autor:innen

continuous glucose monitoringdisease progressionearly-stage diagnosisglucose variabilitypediatricstype 1 diabetes

Substanzen

Blood GlucoseAutoantibodies

Autor:innen und Institutionen

  • Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich 80939, Germany.
  • Forschergruppe Diabetes at Klinikum rechts der Isar, School of Medicine, Technical University Munich, Munich 80939, Germany.
  • Faculty of Medicine, Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden 01307, Germany.
  • Paul Langerhans Institute Dresden of the Helmholtz Munich at University Hospital Carl Gustav Carus and Faculty of Medicine, TU Dresden, Dresden 01307, Germany.

ORCID-Profile: Elisabeth Huber, Tarini Singh, Melanie Bunk, Mayscha Hebel, Kerstin Kick, Andreas Weiß, Mirjam Kohls, Melanie Köger, Maja Hergl, Jose Maria Zapardiel Gonzalo, Ezio Bonifacio, Anette-G Ziegler

Förderung

  • German Center for Diabetes Research
  • LifeScience-Stiftung
  • Juvenile Diabetes Research Foundation International
  • Helmsley Charitable Trust

Zitieren

APA

Huber, E., Singh, T., Bunk, M., Hebel, M., Kick, K., Weiß, A., Kohls, M., Köger, M., Hergl, M., Zapardiel Gonzalo, J. M., Bonifacio, E., & Ziegler, A. G. (2025). Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae691

Vancouver

Huber E, Singh T, Bunk M, Hebel M, Kick K, Weiß A, et al. Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae691

BibTeX
@article{Huber2025,
  author = {Huber, Elisabeth and Singh, Tarini and Bunk, Melanie and Hebel, Mayscha and Kick, Kerstin and Weiß, Andreas and Kohls, Mirjam and Köger, Melanie and Hergl, Maja and Zapardiel Gonzalo, Jose Maria and Bonifacio, Ezio and Ziegler, Anette-G},
  title = {Discrimination and Precision of Continuous Glucose Monitoring in Staging Children With Presymptomatic Type 1 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae691}
}
Kostenlos starten →